Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1105281.RAVbNmMXGmcgoMRwN5GB-Vb8Fl_YLGxxTdWiYZEN2Mt0g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1105281.RAVbNmMXGmcgoMRwN5GB-Vb8Fl_YLGxxTdWiYZEN2Mt0g130_assertion type Assertion NP1105281.RAVbNmMXGmcgoMRwN5GB-Vb8Fl_YLGxxTdWiYZEN2Mt0g130_head.
- NP1105281.RAVbNmMXGmcgoMRwN5GB-Vb8Fl_YLGxxTdWiYZEN2Mt0g130_assertion description "[The rationale of ?1-antitrypsin (AAT) augmentation therapy to treat progressive emphysema in AAT-deficient patients is based on inhibition of neutrophil elastase; however, the benefit of this treatment remains unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1105281.RAVbNmMXGmcgoMRwN5GB-Vb8Fl_YLGxxTdWiYZEN2Mt0g130_provenance.
- NP1105281.RAVbNmMXGmcgoMRwN5GB-Vb8Fl_YLGxxTdWiYZEN2Mt0g130_assertion evidence source_evidence_literature NP1105281.RAVbNmMXGmcgoMRwN5GB-Vb8Fl_YLGxxTdWiYZEN2Mt0g130_provenance.
- NP1105281.RAVbNmMXGmcgoMRwN5GB-Vb8Fl_YLGxxTdWiYZEN2Mt0g130_assertion SIO_000772 23975926 NP1105281.RAVbNmMXGmcgoMRwN5GB-Vb8Fl_YLGxxTdWiYZEN2Mt0g130_provenance.
- NP1105281.RAVbNmMXGmcgoMRwN5GB-Vb8Fl_YLGxxTdWiYZEN2Mt0g130_assertion wasDerivedFrom befree-2016 NP1105281.RAVbNmMXGmcgoMRwN5GB-Vb8Fl_YLGxxTdWiYZEN2Mt0g130_provenance.
- NP1105281.RAVbNmMXGmcgoMRwN5GB-Vb8Fl_YLGxxTdWiYZEN2Mt0g130_assertion wasGeneratedBy ECO_0000203 NP1105281.RAVbNmMXGmcgoMRwN5GB-Vb8Fl_YLGxxTdWiYZEN2Mt0g130_provenance.